PMID: 6970069Jan 1, 1981Paper

The consequences of the chemotherapy of Hodgkin's disease: The 10th David A. Karnofsky Memorial Lecture

Cancer
V T DeVita

Abstract

The most important consequence of using chemotherapy for Hodgkin's disease is its cure. Results of the MOPP program, developed at the National Cancer Institute in 1964, indicate that the majority of the 80% of patients who attain complete remission, who are at risk for ten years, have remained disease-free. The presence of symptoms and the histologic subtype, nodular sclerosis, has had important negative influences on prognosis. Review of three long-term adverse consequences of chemotherapy revealed sterility to be the most significant effect of drug treatment in this young population. Adverse effects of the immunosuppressive drugs in MOPP proved to be minimal. The carcinogenic effect of MOPP when used alone was surprisingly small, but increased significantly when combined with irradiation. National mortality from Hodgkin's disease has decreased abruptly since the introduction of effective chemotherapy for Hodgkin's disease in 1970.

References

Apr 26, 1975·Lancet·G P CanellosR E Johnson
Nov 3, 1977·The New England Journal of Medicine·J S GoodwinR C Williams
Feb 1, 1978·The American Journal of Medicine·C A BrownA C Aisenberg
Dec 8, 1977·The New England Journal of Medicine·C N ColemanH S Kaplan
May 1, 1976·Cancer·A C Aisenberg, R Qazi
Jan 24, 1974·The New England Journal of Medicine·R Levy, H S Kaplan
May 10, 1973·The New England Journal of Medicine·V T DeVita, P S Schein
Apr 1, 1972·The Journal of Clinical Investigation·D H Van ThielV T De Vita
Jul 30, 1972·Bollettino della Società italiana di biologia sperimentale·G S Del GiaccoV Grifoni
Jan 1, 1973·Revue Roumaine De Médecine Interne·M GociuS Berceanu
Feb 5, 1968·JAMA : the Journal of the American Medical Association·E M JacobsD A Wood
Sep 1, 1972·Clinical Pharmacology and Therapeutics·G P CannellosV T DeVita
Jan 1, 1972·The American Journal of Medicine·R C YoungV T DeVita
Jan 1, 1965·Advances in Chemotherapy·E Frei, E J Freireich
Dec 1, 1969·Proceedings of the Society for Experimental Biology and Medicine·B A ChabnerV T Oliverio
Jul 1, 1970·Cell and Tissue Kinetics·R C Young, V T DeVita
Dec 1, 1970·Annals of Internal Medicine·V T DevitaP P Carbone
Aug 26, 1971·The New England Journal of Medicine·R C YoungG P Canellos
Jul 1, 1966·Clinical Pharmacology and Therapeutics·V T DeVitaP P Carbone
Mar 1, 1965·Clinical Pharmacology and Therapeutics·E FREIS P MILLER

❮ Previous
Next ❯

Citations

Jan 1, 1983·American Journal of Industrial Medicine·R M Chapman
Jan 1, 1987·Journal of Cancer Research and Clinical Oncology·E D KreuserH Heimpel
Jun 1, 1985·World Journal of Surgery·M A TaylorT S Nelsen
Mar 1, 1984·Cancer Treatment Reviews·K Rieche
Aug 1, 1988·Journal of Pediatric Surgery·A L Schneeberger, D P Girvan
Jan 13, 2001·Molecular and Cellular Endocrinology·G Bahadur
Jun 23, 2000·Critical Reviews in Oncology/hematology·H EghbaliP Richaud
May 7, 1981·The New England Journal of Medicine·S StrickerR W Carey
Oct 8, 1981·The New England Journal of Medicine
Apr 1, 1982·The New England Journal of Medicine·A SantoroP Valagussa
Apr 1, 1982·The New England Journal of Medicine·R J Mayer
Sep 9, 1982·The New England Journal of Medicine
Oct 6, 1983·The New England Journal of Medicine·L R ProsnitzJ B Weissberg
Jul 14, 1990·BMJ : British Medical Journal·C J Williams
Apr 1, 1983·Postgraduate Medical Journal·T A Lister, J S Malpas
Sep 1, 1996·Thorax·J S Billing, F C Wells
Jul 10, 1998·Journal of Toxicology. Clinical Toxicology·W J Meggs, R S Hoffman
Dec 1, 1986·The American Journal of the Medical Sciences·B P Grubb, M Thant
Apr 1, 1986·International Journal of Radiation Oncology, Biology, Physics·V T DeVitaS A Rosenberg
Jan 1, 1985·International Journal of Radiation Oncology, Biology, Physics·S A Rosenberg, H S Kaplan
Feb 1, 1985·Seminars in Oncology Nursing·S H KaempferE A Rhodes
Mar 17, 2010·Hematological Oncology·Marleen A E van der KaaijHanneke C Kluin-Nelemans
Jan 18, 2014·British Journal of Haematology·Dianne PulteUNKNOWN GEKID Cancer Survival Working Group
Dec 1, 1991·American Journal of Surgery·P C MuskatG J Bowers
Sep 1, 1987·The American Journal of Medicine·A C BuzaidT P Miller
Oct 1, 1981·The American Journal of Medicine·R L SchilskyV T DeVita
Jan 1, 1992·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·V BonfanteG Bonadonna
Jan 1, 1991·Journal of Clinical Epidemiology·E J FeuerD T Green
Sep 1, 1984·British Journal of Haematology·G PapaG Bellesi
Feb 1, 1987·International Journal of Andrology·G J Bosl, D Bajorunas
Feb 1, 1989·Seminars in Oncology Nursing·M C Fraser, M A Tucker
Jun 1, 1990·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·H EghbaliA Najman

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.